Medexus Pharmaceuticals Inc.
MEDXF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0.5% | -0.6% | -17.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 55.7% | 56% | 50.2% | 50.7% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 14.2% | 18.1% | 14.9% | 15.4% |
| Net Income | -$0 | $0 | -$0 | $0 |
| % Margin | -1.3% | 2.1% | -2.2% | 2.4% |
| EPS Diluted | -0.01 | 0.016 | -0.02 | 0.03 |
| % Growth | -159.3% | 181.4% | -167% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |